PEYTON HELBING: Open Payments
NPI 1245948405 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,626 in 86 payments from 15 companies in 2025. Trend: 2023 $1,371 · 2024 $1,817 · 2025 $1,626
Food & beverage: $1,626
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $358 |
| ABBVIE INC. | 18 | $233 |
| Novo Nordisk Inc | 14 | $222 |
| Lilly USA, LLC | 10 | $171 |
| PFIZER INC. | 8 | $148 |
| Abbott Laboratories | 4 | $107 |
| Gilead Sciences, Inc. | 3 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $74 |
| Axsome Therapeutics, Inc. | 2 | $63 |
| GlaxoSmithKline, LLC. | 3 | $44 |
Products named: AIRSUPRA, MOUNJARO, Wegovy, PREVNAR 20, FREESTYLE LIBRE 3, UBRELVY, VRAYLAR, Ozempic.
Industry payments across TX — which companies pay providers there.
